Drugs / TBD11
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06707142 | Dec 2024 → Feb 2026 | — | Gates Medical Research Institute | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TBD11 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06707142 ↗ |
| Route | Oral | “TBD11 will be administered orally.” NCT06707142 ↗ |